NEW YORK, Dec 10 (Reuters) - Online telehealth company Hims and Hers Health is launching its weight-loss membership and ...

Hims stock fell Tuesday following a mixed third-quarter report after the telehealth giant said it's in discussions with Novo NordiskNVO to sell Wegovy shots. Hims & Hers HealthHIMS reported $599 ...

Shares of Hims & Hers closed up 23% on Tuesday, while Novo Nordisk's stock closed up 4%. The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally ...

Hims & Hers Health ($HIMS) is strengthening its position in the UK with the launch of weight-loss programs. This launch will ...

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...

The telehealth company Hims & Hers Health is accelerating its international growth strategy, with a new launch in the United Kingdom marking its latest move. This follows closely on the heels of its ...

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to make Wegovy available on its platform. The discussions are about both ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

The telehealth platform was hit earlier this year by the Food & Drug Administration declaring there was no longer a shortage of Ozempic or Wegovy, the GLP-1 drugs sold by Novo Nordisk (NYSE:NVO) for ...

Hims & Hers Health reported strong 3Q25 revenue growth of 49% YoY, despite a GAAP EPS miss and shares falling post-earnings. HIMS is expanding its offerings, including testosterone and potential ...